133 related articles for article (PubMed ID: 29063663)
1. Enhanced natural killer cell activity is found in exposed uninfected recipients of hepatitis C-contaminated blood.
Ow MM; Hegazy D; Warshow UM; Cramp ME
J Viral Hepat; 2018 Mar; 25(3):245-253. PubMed ID: 29063663
[TBL] [Abstract][Full Text] [Related]
2. Protection against hepatitis C infection via NK cells in highly-exposed uninfected injecting drug users.
Sugden PB; Cameron B; Mina M; Lloyd AR;
J Hepatol; 2014 Oct; 61(4):738-45. PubMed ID: 24845613
[TBL] [Abstract][Full Text] [Related]
3. Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro.
Golden-Mason L; Cox AL; Randall JA; Cheng L; Rosen HR
Hepatology; 2010 Nov; 52(5):1581-9. PubMed ID: 20812318
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cells in highly exposed hepatitis C-seronegative injecting drug users.
Mina MM; Cameron B; Luciani F; Vollmer-Conna U; Lloyd AR;
J Viral Hepat; 2016 Jun; 23(6):464-72. PubMed ID: 26833632
[TBL] [Abstract][Full Text] [Related]
5. Altered natural killer cell subset distributions in resolved and persistent hepatitis C virus infection following single source exposure.
Golden-Mason L; Madrigal-Estebas L; McGrath E; Conroy MJ; Ryan EJ; Hegarty JE; O'Farrelly C; Doherty DG
Gut; 2008 Aug; 57(8):1121-8. PubMed ID: 18372499
[TBL] [Abstract][Full Text] [Related]
6. Immunological changes in different patient populations with chronic hepatitis C virus infection.
Szereday L; Meggyes M; Halasz M; Szekeres-Bartho J; Par A; Par G
World J Gastroenterol; 2016 May; 22(20):4848-59. PubMed ID: 27239111
[TBL] [Abstract][Full Text] [Related]
7. Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C.
Nattermann J; Feldmann G; Ahlenstiel G; Langhans B; Sauerbruch T; Spengler U
Gut; 2006 Jun; 55(6):869-77. PubMed ID: 16322112
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus-infected cells downregulate NKp30 and inhibit ex vivo NK cell functions.
Holder KA; Stapleton SN; Gallant ME; Russell RS; Grant MD
J Immunol; 2013 Sep; 191(6):3308-18. PubMed ID: 23960237
[TBL] [Abstract][Full Text] [Related]
9. Spontaneous and natural cytotoxicity receptor-mediated cytotoxicity are effector functions of distinct natural killer subsets in hepatitis C virus-infected chimpanzees.
Verstrepen BE; Nieuwenhuis IG; Mooij P; Bogers WM; Boonstra A; Koopman G
Clin Exp Immunol; 2016 Jul; 185(1):42-9. PubMed ID: 26850369
[TBL] [Abstract][Full Text] [Related]
10. Genetically associated CD16(+)56(-) natural killer cell interferon (IFN)-αR expression regulates signaling and is implicated in IFN-α-induced hepatitis C virus decline.
Conry SJ; Meng Q; Hardy G; Yonkers NL; Sugalski JM; Hirsch A; Davitkov P; Compan A; Falck-Ytter Y; Blanton RE; Rodriguez B; Harding CV; Anthony DD
J Infect Dis; 2012 Apr; 205(7):1131-41. PubMed ID: 22351942
[TBL] [Abstract][Full Text] [Related]
11. Reduced frequencies of NKp30+NKp46+, CD161+, and NKG2D+ NK cells in acute HCV infection may predict viral clearance.
Alter G; Jost S; Rihn S; Reyor LL; Nolan BE; Ghebremichael M; Bosch R; Altfeld M; Lauer GM
J Hepatol; 2011 Aug; 55(2):278-88. PubMed ID: 21168454
[TBL] [Abstract][Full Text] [Related]
12. Increased CD56(bright) NK cells in HIV-HCV co-infection and HCV mono-infection are associated with distinctive alterations of their phenotype.
Bhardwaj S; Ahmad F; Wedemeyer H; Cornberg M; Schulze Zur Wiesch J; van Lunzen J; Sarin SK; Schmidt RE; Meyer-Olson D
Virol J; 2016 Apr; 13():67. PubMed ID: 27091211
[TBL] [Abstract][Full Text] [Related]
13. Interferon-γ production by tubulointerstitial human CD56
Law BMP; Wilkinson R; Wang X; Kildey K; Lindner M; Rist MJ; Beagley K; Healy H; Kassianos AJ
Kidney Int; 2017 Jul; 92(1):79-88. PubMed ID: 28396119
[TBL] [Abstract][Full Text] [Related]
14. Modulation of natural killer (NK) receptors on NK (CD3-/CD56+), T (CD3+/CD56-) and NKT-like (CD3+/CD56+) cells after heart transplantation.
Aguilar P; Mathieu CP; Clerc G; Ethevenot G; Fajraoui M; Mattei S; Faure GC; Bene MC
J Heart Lung Transplant; 2006 Feb; 25(2):200-5. PubMed ID: 16446221
[TBL] [Abstract][Full Text] [Related]
15. Altered natural killer cells subsets distribution in children with hepatitis C following vertical transmission.
Indolfi G; Mangone G; Moriondo M; Serranti D; Bartolini E; Azzari C; Resti M
Aliment Pharmacol Ther; 2016 Jan; 43(1):125-33. PubMed ID: 26470759
[TBL] [Abstract][Full Text] [Related]
16. High frequencies of CD158b+ NK cells are associated with persistent hepatitis C virus infections.
Ji HF; Wang J; Yu L; Niu JQ; Ayana DA; Jiang YF
Ann Hepatol; 2013; 12(4):539-47. PubMed ID: 23813131
[TBL] [Abstract][Full Text] [Related]
17. Activation of natural killer cells during acute infection with hepatitis C virus.
Amadei B; Urbani S; Cazaly A; Fisicaro P; Zerbini A; Ahmed P; Missale G; Ferrari C; Khakoo SI
Gastroenterology; 2010 Apr; 138(4):1536-45. PubMed ID: 20080094
[TBL] [Abstract][Full Text] [Related]
18. Circulating CD56dim natural killer cells and CD56+ T cells that produce interferon-γ or interleukin-10 are expanded in asymptomatic, E antigen-negative patients with persistent hepatitis B virus infection.
Conroy MJ; Mac Nicholas R; Grealy R; Taylor M; Otegbayo JA; O'Dea S; Mulcahy F; Ryan T; Norris S; Doherty DG
J Viral Hepat; 2015 Mar; 22(3):335-45. PubMed ID: 25186004
[TBL] [Abstract][Full Text] [Related]
19. Natural killer cells in perinatally HIV-1-infected children exhibit less degranulation compared to HIV-1-exposed uninfected children and their expression of KIR2DL3, NKG2C, and NKp46 correlates with disease severity.
Ballan WM; Vu BA; Long BR; Loo CP; Michaëlsson J; Barbour JD; Lanier LL; Wiznia AA; Abadi J; Fennelly GJ; Rosenberg MG; Nixon DF
J Immunol; 2007 Sep; 179(5):3362-70. PubMed ID: 17709553
[TBL] [Abstract][Full Text] [Related]
20. Selective reduction of natural killer cells and T cells expressing inhibitory receptors for MHC class I in the livers of patients with hepatic malignancy.
Norris S; Doherty DG; Curry M; McEntee G; Traynor O; Hegarty JE; O'Farrelly C
Cancer Immunol Immunother; 2003 Jan; 52(1):53-8. PubMed ID: 12536240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
